Provided by Tiger Trade Technology Pte. Ltd.

Hutchison China Meditech

12.38
-0.0350-0.28%
Pre-market: 12.550.1700+1.37%05:01 EDT
Volume:59.14K
Turnover:733.41K
Market Cap:2.16B
PE:122.63
High:12.48
Open:12.40
Low:12.34
Close:12.42
52wk High:18.30
52wk Low:9.77
Shares:174.43M
Float Shares:104.00M
Volume Ratio:0.85
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1010
EPS(LYR):2.60
ROE:1.46%
ROA:-1.24%
PB:1.71
PE(LYR):4.76

Loading ...

HUTCHMED to Unveil Data at ASCO 2026 Annual Meeting

Stock News
·
May 22

Hutchmed, Innovent Biologics Win NMPA Approval for Renal Cancer Therapy

MT Newswires Live
·
May 21

Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination

TIPRANKS
·
May 21

Newmark Security Accelerates HCM-Focused Strategy as Revenue and North American Sales Surge

TIPRANKS
·
May 21

Press Release: Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Dow Jones
·
May 20

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

GlobeNewswire
·
May 15

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

GlobeNewswire
·
May 11

Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says

MT Newswires Live
·
May 09

Press Release: Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

Dow Jones
·
May 07

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

GlobeNewswire
·
May 07

Press Release: Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 07

Asure Software Sets May & June 2026 Investor Conference Schedule

GlobeNewswire
·
May 07

Analyst Maintains Buy Rating and $136 Price Target on Aficamten Following Strong Phase 3 ACACIA-HCM Results

TIPRANKS
·
May 06

Press Release: Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Dow Jones
·
May 05

Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

GlobeNewswire
·
May 05

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

GlobeNewswire
·
Apr 30

Hutchmed Says China Grants Priority Review for Sovleplenib in Autoimmune Hemolytic Anemia

MT Newswires Live
·
Apr 29

HUTCHMED's Sovleplenib NDA for Warm Autoimmune Hemolytic Anemia Accepted in China with Priority Review and Breakthrough Therapy Designation

Stock News
·
Apr 29

Sage launches Sage HCM to connect HR, payroll and finance for mid-market businesses

GlobeNewswire
·
Apr 23

EX3 Accelerates APAC Expansion with Malaysia Growth Milestone and SAP Partnership

prnewswire
·
Apr 21